SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

A sharp rebound is drawing attention to NASAs CLPS 2.0 lunar-delivery program and the prospect of future task orders for Intuitive Machines, alongside anticipation of upcoming earnings. Traders are debating whether the companys eligibility to compete will translate into meaningful awards, while some attribute the bounce to short covering.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys engine, technology-licensing and engineering agreement with AST SpaceMobile for its planned rocket is driving attention, with traders viewing the deal as validation of Fireflys propulsion business and a boost to its backlog. Some are cautious about the stock component and financing details, execution risks, and the upcoming earnings report.

GLOBALFOUNDRIES, Inc. provides foundry services and manufactures semiconductors. It offers global shuttle, mask, post-fab and turnkey services. The company was founded on October 7, 2008 and is headquartered in Malta, NY.

GlobalFoundries Inc

GlobalFoundries recent earnings beat and stronger profit guidance are drawing attention, but shares have remained volatile amid analyst price-target cuts and bearish options positioning. Traders are split between concerns about mature-node demand and contract renewals, and the view that the selloff is overdone and the results support a rebound.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is drawing attention ahead of its earnings report, with traders focused on whether AI data-center networking demand can offset weaker or delayed traditional network refresh spending; guidance and margins are a key point of debate. The recent selloff and analyst caution have frustrated bears and holders, while some traders see AI infrastructure demand as a reason to buy the dip.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Analyst upgrades and Zeta Live announcements are driving attention: traders are weighing Goldman Sachs Buy upgrade and optimism around the new AthenaOS platform and AI partnerships against questions about execution and whether the products will translate into revenue. Many are positioning ahead of earnings, while others are cautious about the stocks ability to sustain its gains amid broader tech-market weakness.

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Bicara Therapeutics Inc.

Bicara Therapeutics

Bicara shares are being discussed in the wake of positive Phase 3 results from competitor Genmab, which traders believe raised competitive concerns for Bicaras head-and-neck cancer drug and contributed to a sharp selloff. The community is split between viewing the decline as justified by the competitive threat and calling it an overreaction, with bullish posters pointing to Bicaras differentiated therapy and upcoming pivotal-trial data.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks strong quarterly results and raised full-year outlook have drawn attention, but shares sold off as traders questioned the slower cloud net-new ARR outlook and managements guidance. Bulls view the business and AI-related cyber-resilience demand as intact, while skeptics argue that high expectations and management credibility concerns could keep pressure on the stock.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemons steep decline and Michael Burrys reported exit of his position for tax-loss reasons dominate discussion, alongside concerns about weakening demand, competition, and the companys turnaround. Traders are split between viewing the selloff and Burrys departure as further downside signals and seeing the beaten-down valuation and new leadership as potential reasons for a rebound.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 10.7808229 USD and is down -0.30 over the last 24 hours. It is currently trading on 2314 active market(s) with $147,808,096.15 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rebound and breakout have drawn attention, with traders connecting the move to institutional and tokenization developments, including Coinbases reported selection of Chainlink infrastructure for tokenized stocks on Base. Bulls view adoption as a long-term tailwind, while skeptics question whether that utility will translate into token value and warn the rally could fade.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluences renewed FY2026 outlook cut, driven by continued Houston manufacturing delays, has put execution problems and the companys ability to convert its backlog into revenue at the center of discussion. Traders are split between concerns about management credibility and operations and dip-buyers who see persistent storage demand and new operations leadership as possible reasons for a turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nyxoah SA (NYXH) Reports Q3 Loss, Lags Revenue Estimates

Nyxoah (NYXH) delivered earnings and revenue surprises of +16.67% and -5.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

OMCL vs. VEEV: Which Stock Should Value Investors Buy Now?

OMCL vs. VEEV: Which Stock Is the Better Value Option?

UCB Selects Veeva Vault CRM

UCB Selects Veeva Vault CRM UCB Selects Veeva Vault CRMPR NewswirePLEASANTON, Calif., Nov. 4, 2026 Agentic CRM platform to drive unified engagement worldwidePLEASANTON, Calif., Nov. 4, 2026 /PRNewswire/ -- Veeva Systems(NYSE: VEEV) today announced that UCB has committed to Veeva Vault CRM, the...

Hinge Health Inc. (HNGE) Beats Q3 Earnings and Revenue Estimates

Hinge Health Inc. (HNGE) delivered earnings and revenue surprises of +12.70% and +4.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Veeva Systems (VEEV) Dipped More Than Broader Market Today

Veeva Systems (VEEV) reached $307 at the closing of the latest trading day, reflecting a -1.9% change compared to its last close.

Is It Worth Investing in Veeva (VEEV) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It

Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Veeva Systems (VEEV) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Veeva Systems (VEEV) stood at $318.18, denoting a -1.5% move from the preceding trading day.

Veeva Systems (VEEV) Rises Higher Than Market: Key Facts

In the most recent trading session, Veeva Systems (VEEV) closed at $316.8, indicating a +2.08% shift from the previous trading day.

Is Veeva (VEEV) a Buy as Wall Street Analysts Look Optimistic?

According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. The firm's solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. Its customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. The firm's regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. Its customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Michael Burry Stays Bullish On VEEV, Calls SNOW 'Overvalued' — And Revisits 'Big Short' Thesis That Best Stocks Fall By Half First

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Burry indicated that he would use a pullback in VEEV to build a larger position.</li><li>He warned Snowflake could face longer-term risks from cyberattacks on data lakes as AGI and quantum computing advance.</li><li>The investor said technical analysis helps him manage entry points while limiting the psychological biases that can come with owning a stock.</li></ul>"The Big Short" investor Michael Burry has reiterated his bullish view on Veeva Systems but said he recently trimmed his position after a sharp rally carried shares to a key resistance level. In the same Substack chat session, he called Snowflake stock "very overvalued," offering a window into his latest thinking on individual names.Burry disclosed a position in VEEV in April, making the stock one of its key picks in a software-rebound thesis. In May, he said “VEEV is still cheap,” arguing that the market had punished the life-sciences software company more severely than its underlying fundamentals warranted, and increased his exposure to the stock.The position became one of the more significant holdings in his portfolio, alongside other beaten-down software names such as Adobe.&nbsp;A key part of Burry’s Veeva thesis is that the company’s core Vault platform is less vulnerable to competition and disruption than its CRM business. While Salesforce poses a competitive threat in CRM, Burry reportedly believes that the broader Veeva franchise, particularly its life-sciences-focused software, remains relatively well protected.“A stock that was recently beaten down rising very fast to a level of significant resistance/overhead pressure could lead me to trim the position. It would not lead me to sell it outright. This happened with VEEV recently which also coincided with a much higher valuation,” Burry posted in his&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://michaeljburry.substack.com/chat/posts/ac8f7c9d-3881-4866-a5cd-5dd09f8b16d9">chat group</a>.<a href="https://stocktwits.com/symbol/VEEV">VEEV stock</a> has climbed sharply from lows in May, and rose 15% last Thursday after reporting upbeat earnings.<h2 class="st-heading-2">Burry Sees SNOW As Overvalued</h2>On Snowflake, Burry said that not only is the stock overvalued but the company “also faces an existential threat if the ecosystem of data lakes is proven too vulnerable to cyberattack if/when AGI and quantum computing becomes available.”“The headwinds would be lesser if companies develop their own AI departments and decide to keep more data in-house.”&nbsp;On Wednesday, Snowflake beat Wall Street estimates for quarterly ​results and raised its full-year product revenue forecast, signaling robust demand for its ‌cloud data platform and AI offerings and sending its shares surging over 20% in overnight trading.<h2 class="st-heading-2">‘The Big Short’ Book: Burry’s Investing Style&nbsp;&nbsp;</h2>Burry said he embraces sharp declines in stocks when they create an opportunity to build larger positions at cheaper prices.&nbsp;Referring to a comment by his longtime friend Jim Clarke of Brandywine in Michael Lewis’ 2010 book “The Big Short,” Burry recalled the idea that the “perfect Burry stock” is one that falls by half before eventually rising several times over. Burry said he has used technical analysis to improve on that approach, while also acknowledging the advantage of being able to buy more of a company when its stock falls.Burry pointed to Molina Healthcare and Veeva as examples where lower prices allowed him to accumulate much larger positions. He also noted that being invested in a stock can deepen his understanding of the company, but can simultaneously introduce psychological biases. His approach, he said, is to “try to push the former up and keep the other down” — meaning he wants to increase his understanding of an investment while keeping emotional and psychological biases under control.Overall, Burry’s Veeva trade appears to be a bet on a re-rating of high-quality SaaS stocks after the AI-driven selloff.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kimi-k3-operator-moonshot-reportedly-files-for-hong-kong-ipo-as-china-s-ai-advances-weigh-on-open-ai-anthropic/cZsMNruRJHq">Kimi K3 Operator Moonshot Reportedly Files For Hong Kong IPO As China’s AI Advances Weigh On OpenAI, Anthropic</a>&nbsp;

The Veeva Systems, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on December 31, 2024. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

The investor says sharp selloffs can create opportunities to accumulate more shares, while cautioning that conviction must be balanced against valuation and risk.

Molina Healthcare Inc

Snowflake Inc

Track VEEV stock price, charts, news and real-time market activity on Stocktwits. Join the VEEV message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Veeva Systems Inc stock.

VEEV Stock Price Today - Veeva Systems Inc News, Charts, Retail Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$VEEV yesterday I bought this for the first time. I plan on trading it only as I don't understand the business. But the fundamentals are strong too and the growth is stable. Might take a deeper look into $VEEV  
 
$SPY $PLTR $HIMS

$VEEV ai inside a regulated trial system has to be validated, audited and signed off. seems like that paperwork is the real rollout timeline, and a demo that ships fast is not the product drug firms can actually use

Clam Clamwell

$VEEV Way overbought, high RSI, PE is meh, and the short interested did not even change... It's not even shorter yet, but it will be soon.

Andy Flyer

$VEEV pharma software renewals sit behind trial costs that cannot be cut. seems like when drug budgets tighten, the back office system is negotiated harder, not the study that might actually sell

Haven’t employed this strategy in a long time… it’s called hold your nuts and pray $VEEV

Yoda

$VEEV a drug trial runs for years and every change gets revalidated. seems like bolting ai onto a slow, audited process does not speed the sale, it adds another approval queue inside the approval queue

I've got an alert on $VEEV above today's high.  Would like to grab it there on a reversal from the pink zone.

Dr. Stoxx

$VEEV a close over $332.71 will send this much higher.  Should see that by end of the week followed by a steady climb into earnings on 12/9.

jean

$VEEV engaged long on our focus list on 9/28, using this break above DT line price pattern. The Nov 270 calls paid out +268%

Feed

News

Sentiment

Earnings

Fundamentals

Info

VEEV Veeva Systems Inc - Ordinary Shares - Class A

Fundamentals

Latest VEEV News